局所ドラッグデリバリー市場：タイプ（半固形（クリーム、ゲル、ローション）、固形（坐剤）、液体（溶液）、経皮吸収製品）、ルート（経皮、眼科）、使用施設（在宅医療、病院、熱傷センター）- 2027年までの世界予測

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) - Global Forecast to 2027

局所ドラッグデリバリーの世界市場は、2022年の2074億米ドルから2027年には年平均成長率8.9％で3178億米ドルに達すると予測されます。この市場の成長は、ドライアイ疾患に対する局所処方療法の高い普及率、スマー... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2022年5月26日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	297	284	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

局所ドラッグデリバリーの世界市場は、2022年の2074億米ドルから2027年には年平均成長率8.9％で3178億米ドルに達すると予測されます。この市場の成長は、ドライアイ疾患に対する局所処方療法の高い普及率、スマートな経皮ドラッグデリバリーシステムの研究開発に対する製薬会社の関心の高まり、中枢神経疾患の有病率の増加、非侵襲的ドラッグデリバリー方法に対する好みの高まりなどが主因として挙げられます。

"2021年の製品別、局所ドラッグデリバリー市場では、半固形製剤セグメントが最大のシェアを占めています。"
製品に基づき、局所ドラッグデリバリー市場は、半固形製剤、液体製剤、固形製剤、経皮製剤に区分されます。半固形製剤のシェアが大きいのは、副作用が少なく患者のアドヒアランスが良いこと、吸収率が高いこと、薬物放出の効率が良いこと、消化管に害を与えないことなどが要因として挙げられます。

"皮膚薬物送達は、市場の最大のシェアを占めています。"
投与経路に基づき、市場は皮膚、眼科、直腸、膣、鼻腔の薬物送達に区分される。皮膚ドラッグデリバリー市場セグメントの大きなシェアは、規制要件が少ないためアクセスしやすい製品の上市と採用、皮膚から送達されるため薬剤の浸透・浸潤の強化、鼻腔や眼科ドラッグデリバリーと比較して患者への刺激が少ないことが大きく起因していると考えられます。

"使用施設別では、ホームケア現場が最大のシェアを占める"
使用施設に基づき、市場はホームケア環境、病院・診療所、火傷センター、その他の施設に区分されます。在宅医療分野のシェアが高い理由としては、患者の快適性の向上、在宅医療に関する意識の高まりによる患者の受け入れ態勢の改善、COVID-19の流行による入院患者の減少、病院や介護施設での治療から在宅医療への移行による費用対効果の高さ、などが挙げられます。

"予測期間中、APACが最も高い成長を遂げる"
アジア太平洋地域は、2022-2027年の予測期間中に最も高いCAGRで成長すると予想されています。皮膚疾患（皮膚癌など）の発生率の高さ、慢性疾患（糖尿病など）の有病率の上昇、避妊具の使用の増加、老人人口の増加、スマート経皮薬物送達システムの研究開発に製薬会社が注力していることなどが、アジア太平洋地域における局所薬物送達市場の成長を促進する主要因として期待されます。

主な参加企業の内訳は以下の通りです。
- 企業タイプ別 - Tier 1-35%、Tier 2-45%、Tier 3-20
- 役職別：Cレベル-35％、ディレクターレベル-25％、その他-40
- 地域別：北米-45%、欧州-30%、アジア太平洋-20%、中南米-3%、中東・アフリカ-2

局所ドラッグデリバリー市場の主要企業

局所ドラッグデリバリー市場の主要プレイヤーは、Glenmark Pharmaceuticals Ltd.(インド）、Galderma（スイス）、Johnson & Johnson Private Limited（米国）、GlaxoSmithKline Plc.（英国）、Bausch Health Ltd.（米国）。(英国）、ボシュ・ヘルス・カンパニーズ社（カナダ）、久光製薬株式会社（日本）、シプラ社（インド）、Bayer AG（ドイツ）、Viatris Inc（マイラン社）（米国）、3M（米国）、Merck & Co.Inc.社（ドイツ）。(ドイツ)、Crescita Therpeautics Inc.（カナダ）、Novartis International AG（スイス）、Boehringer Ingelheim International GmBH（ドイツ）、Pfizer Inc（米国）、Teva Pharmaceuticals Industries Ltd. (米国)、Bristol Mython Inc.(イスラエル）、Bristol Myers Squibb（米国）、リードケミカル株式会社（日本）、パデュー・ファルマ株式会社（日本）、株式会社エー・エム・ティー・エス（日本）。(日本）、Purdue Pharma L.P.（米国）、Lavipharm（ギリシャ）、AbbVie Inc.（米国）、CMP Pharma, Inc（ドイツ）、Encore Dermatology, Inc（米国）、Prosolus Inc.（米国）およびRusan Pharma Ltd. （インド）。(インド）。

調査対象
本レポートでは、局所ドラッグデリバリー市場を分析し、製品、投与経路、使用施設、地域などの様々なセグメントに基づいて、同市場の市場規模および今後の成長可能性を推定することを目的としています。また、市場で入手可能な様々な外用薬物送達製品の製品ポートフォリオマトリックスも掲載しています。また、同市場の主要企業の競争力分析も行っており、企業プロファイル、製品提供、主要な市場戦略も併せて掲載しています。

本レポートを購入する理由
本レポートは、既存企業だけでなく、新規参入企業や小規模企業が市場の脈拍を測定することを可能にし、その結果、市場でのより大きなシェアを獲得するのに役立つでしょう。本レポートを購入された企業は、以下の戦略のいずれか、または組み合わせて使用することで、市場での地位を強化することができます。

本レポートでは、以下のポイントについて考察しています。
- 市場浸透度。局所ドラッグデリバリー市場のトッププレイヤーが提供する製品ポートフォリオに関する包括的な情報。製品別、投与経路別、使用施設別に市場を分析しています。
- 製品の強化/革新。世界の局所ドラッグデリバリー市場における今後の動向と製品上市に関する詳細な洞察
- 市場開発。製品別、投与経路別、使用施設別の有利な新興市場に関する包括的な情報
- 市場の多様化。新製品や製品の強化、成長地域、最近の開発、世界の局所ドラッグデリバリー市場における投資に関する詳細な情報
- 競争力の評価。世界の局所ドラッグデリバリー市場における主要企業の市場シェア、成長戦略、製品オファリング、競合のリーダーシップマッピング、能力に関する詳細な評価。

ページTOPに戻る

1 INTRODUCTION 36
1.1 STUDY OBJECTIVES 36
1.2 MARKET DEFINITION AND SCOPE 36
1.2.1 INCLUSIONS & EXCLUSIONS 36
1.2.2 MARKETS COVERED 37
FIGURE 1 TOPICAL DRUG DELIVERY MARKET SEGMENTATION 37
1.2.3 YEARS CONSIDERED 37
1.3 CURRENCY 38
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 38
1.4 STAKEHOLDERS 38
1.5 SUMMARY OF CHANGES 39
2 RESEARCH METHODOLOGY 40
2.1 RESEARCH DATA 40
FIGURE 2 RESEARCH DESIGN 40
2.1.1 SECONDARY DATA 41
2.1.1.1 Key data from secondary sources 42
2.1.2 PRIMARY DATA 42
FIGURE 3 PRIMARY SOURCES 42
2.1.2.1 Key data from primary sources 43
2.1.2.2 Key industry insights 44
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE
AND DEMAND SIDE PARTICIPANTS 44
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE PARTICIPANTS 45
2.2 MARKET SIZE ESTIMATION 45
FIGURE 6 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS 46
FIGURE 7 TOPICAL DRUG DELIVERY MARKET - REVENUE SHARE
ANALYSIS ILLUSTRATION: JOHNSON & JOHNSON 46
FIGURE 8 PHARMACEUTICAL SALES APPROACH 47
FIGURE 9 TOP-DOWN APPROACH 48
FIGURE 10 CAGR PROJECTIONS 49
FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
IN TOPICAL DRUG DELIVERY MARKET (2022–2027): IMPACT
ON MARKET GROWTH & CAGR 49
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 50
FIGURE 12 DATA TRIANGULATION METHODOLOGY 51
2.4 MARKET SHARE ANALYSIS 52
2.5 STUDY ASSUMPTIONS 52
2.6 LIMITATIONS 53
2.6.1 METHODOLOGY-RELATED LIMITATIONS 53
2.6.2 SCOPE-RELATED LIMITATIONS 53
2.7 RISK ASSESSMENT 53
TABLE 2 RISK ASSESSMENT: TOPICAL DRUG DELIVERY MARKET 53
3 EXECUTIVE SUMMARY 54
FIGURE 13 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2022 VS. 2027 (USD BILLION) 54
FIGURE 14 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION,
2022 VS. 2027 (USD BILLION) 55
FIGURE 15 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2022 VS. 2027 (USD BILLION) 56
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF TOPICAL DRUG DELIVERY MARKET 57
4 PREMIUM INSIGHTS 58
4.1 TOPICAL DRUG DELIVERY MARKET OVERVIEW 58
FIGURE 17 HIGH PREVALENCE OF SKIN DISEASES AND HIGH INCIDENCE
OF BURN INJURIES TO DRIVE MARKET GROWTH 58
4.2 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT AND COUNTRY (2021) 59
FIGURE 18 SEMI-SOLID FORMULATIONS TO DOMINATE
LATIN AMERICA MARKET IN 2021 59
4.3 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 60
FIGURE 19 INDIA TO REGISTER HIGHEST GROWTH IN MARKET
DURING FORECAST PERIOD 60
4.4 TOPICAL DRUG DELIVERY MARKET, BY REGION (2020–2027) 61
FIGURE 20 NORTH AMERICA TO DOMINATE MARKET IN 2027 61
4.5 TOPICAL DRUG DELIVERY MARKET: DEVELOPED VS. DEVELOPING MARKETS 61
FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH
RATES DURING FORECAST PERIOD 61
5 MARKET OVERVIEW 62
5.1 INTRODUCTION 62
5.2 MARKET DYNAMICS 62
TABLE 3 TOPICAL DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 62
5.2.1 DRIVERS 63
5.2.1.1 High prevalence of skin diseases 63
5.2.1.2 Increase in self-medication as a popular practice in dermatology 64
5.2.1.3 High prevalence of topical prescription therapy for dry eye diseases 64
5.2.1.4 Switching from conventional needle injections to
transdermal patches 65
5.2.1.5 High incidence of burn injuries 65
5.2.1.6 Growing prevalence of diabetes 66

5.2.2 RESTRAINTS 66
5.2.2.1 Continuous irritation of skin and allergies caused by topical drugs 66
5.2.2.2 Preference for alternative modes of drug delivery 67
5.2.3 OPPORTUNITIES 67
5.2.3.1 Rising demand for self-administration and home care 67
5.2.3.2 Delivery of biologics through transdermal route 67
5.2.3.3 Topical vehicles used in cosmetic industry 68
5.2.4 CHALLENGES 68
5.2.4.1 Topical formulations for drugs with limited plasma concentration 68
5.2.4.2 Increasing number of drug failures and product recalls 69
5.3 INDUSTRY TRENDS 69
5.3.1 NEW ADVANCEMENT IN TRANSDERMAL DRUG DELIVERY SYSTEM 69
5.3.2 ADOPTION OF TELEDERMATOLOGY 70
5.4 KEY CONFERENCES & EVENTS IN 2022-2023 70
TABLE 4 TOPICAL DRUG DELIVERY MARKET: DETAILED LIST OF
CONFERENCES & EVENTS 70
5.5 IMPACT OF COVID-19 71
5.6 REGULATORY ANALYSIS 72
TABLE 5 REGULATORY SCENARIO, BY COUNTRY 72
5.7 VALUE CHAIN ANALYSIS 75
FIGURE 22 TOPICAL DRUG DELIVERY MARKET: VALUE CHAIN ANALYSIS 75
5.8 ECOSYSTEM MAPPING 76
FIGURE 23 PHARMACEUTICAL DRUG DELIVERY MARKET ECOSYSTEM 76
5.9 TECHNOLOGY ANALYSIS 76
5.10 PRICING ANALYSIS 77
TABLE 6 REGIONAL PRICING ANALYSIS OF TOPICAL DRUGS, 2021 (USD) 77
5.11 PORTER’S FIVE FORCES ANALYSIS 78
TABLE 7 TOPICAL DRUG DELIVERY MARKET: PORTER’S FIVE FORCES ANALYSIS 78
5.11.1 THREAT OF NEW ENTRANTS 78
5.11.2 THREAT OF SUBSTITUTES 79
5.11.3 BARGAINING POWER OF SUPPLIERS 79
5.11.4 BARGAINING POWER OF BUYERS 79
5.11.5 INTENSITY OF COMPETITIVE RIVALRY 79
5.12 PATENT ANALYSIS 79
5.12.1 PATENT PUBLICATION TRENDS FOR TOPICAL DRUG DELIVERY 80
FIGURE 24 PATENT PUBLICATION TRENDS (JANUARY 2011– APRIL 2022) 80
5.12.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 80
FIGURE 25 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS)
FOR TOPICAL DRUG DELIVERY PATENTS (JANUARY 2011–APRIL 2022) 81
FIGURE 26 TOP APPLICANT COUNTRIES/REGIONS FOR TOPICAL DRUG DELIVERY (JANUARY 2011–APRIL 2022) 82
TABLE 8 LIST OF PATENTS/PATENT APPLICATIONS IN TOPICAL
DRUG DELIVERY MARKET, 2021–2022 82
6 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT 84
6.1 INTRODUCTION 85
TABLE 9 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION) 85
6.2 SEMI-SOLID FORMULATIONS 86
TABLE 10 KEY TOPICAL DRUG DELIVERY SEMI-SOLID FORMULATIONS AVAILABLE 86
TABLE 11 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 87
TABLE 12 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY COUNTRY, 2020–2027 (USD BILLION) 87
6.2.1 OINTMENTS 88
6.2.1.1 Ointments to be widely used in analgesic indications 88
TABLE 13 TOPICAL DRUG DELIVERY MARKET FOR OINTMENTS, BY COUNTRY,
2020–2027 (USD BILLION) 88
6.2.2 CREAMS 89
6.2.2.1 Creams to be most widely used formulation due to better absorption 89
TABLE 14 TOPICAL DRUG DELIVERY MARKET FOR CREAMS, BY COUNTRY,
2020–2027 (USD BILLION) 90
6.2.3 LOTIONS 90
6.2.3.1 Easy administration of lotions to drive demand 90
TABLE 15 TOPICAL DRUG DELIVERY MARKET FOR LOTIONS, BY COUNTRY,
2020–2027 (USD BILLION) 91
6.2.4 GELS 91
6.2.4.1 Faster drug release and greater patient acceptability to
drive gels market 91
TABLE 16 TOPICAL DRUG DELIVERY MARKET FOR GELS, BY COUNTRY,
2020–2027 (USD BILLION) 92
6.2.5 PASTES 92
6.2.5.1 Topical pastes to treat and prevent skin irritation 92
TABLE 17 TOPICAL DRUG DELIVERY MARKET FOR PASTES, BY COUNTRY,
2020–2027 (USD BILLION) 93
6.3 LIQUID FORMULATIONS 93
TABLE 18 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 94
TABLE 19 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY COUNTRY, 2020–2027 (USD BILLION) 94
TABLE 20 KEY LIQUID FORMULATIONS AVAILABLE 95
6.3.1 SUSPENSIONS 95
6.3.1.1 Higher rate of bioavailability and controlled onset of action to support market growth 95
TABLE 21 TOPICAL DRUG DELIVERY MARKET FOR SUSPENSIONS, BY COUNTRY,
2020–2027 (USD BILLION) 96
6.3.2 SOLUTIONS 96
6.3.2.1 Topical solutions with soluble chemicals to dissolve in various solvents 96
TABLE 22 TOPICAL DRUG DELIVERY MARKET FOR SOLUTIONS, BY COUNTRY,
2020–2027 (USD BILLION) 97
6.4 SOLID FORMULATIONS 97
TABLE 23 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 98
TABLE 24 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY COUNTRY, 2020–2027 (USD BILLION) 98
TABLE 25 KEY SOLID FORMULATIONS AVAILABLE 99
6.4.1 POWDERS 99
6.4.1.1 Inexpensive manufacturing and effectiveness against antifungal infections to propel powders market 99
TABLE 26 TOPICAL DRUG DELIVERY MARKET FOR POWDERS, BY COUNTRY,
2020–2027 (USD BILLION) 100
6.4.2 SUPPOSITORIES 100
6.4.2.1 Suppositories require suitable base to ensure drug
compatibility and stability 100
TABLE 27 TOPICAL DRUG DELIVERY MARKET FOR SUPPOSITORIES
, BY COUNTRY, 2020–2027 (USD BILLION) 101
6.5 TRANSDERMAL PRODUCTS 102
TABLE 28 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 102
TABLE 29 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY COUNTRY, 2020–2027 (USD BILLION) 103
TABLE 30 KEY TRANSDERMAL PRODUCTS AVAILABLE 103
6.5.1 TRANSDERMAL PATCHES 104
6.5.1.1 Transdermal patches to offer increased drug permeability across skin 104
TABLE 31 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES,
BY COUNTRY, 2020–2027 (USD BILLION) 105
6.5.2 TRANSDERMAL SEMI-SOLIDS 105
6.5.2.1 Transdermal semi-solids to offer fast drying on application site 105
TABLE 32 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL SEMI-SOLIDS,
BY COUNTRY, 2020–2027 (USD BILLION) 106
7 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION 107
7.1 INTRODUCTION 108
TABLE 33 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION,
2020–2027 (USD BILLION) 108
7.2 DERMAL DRUG DELIVERY 109
7.2.1 NANO-SIZED DRUG CARRIER SYSTEMS TO BE STUDIED TO
OVERCOME DRUG PENETRATION LIMITATION 109
TABLE 34 DERMAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 110
7.3 OPHTHALMIC DRUG DELIVERY 110
7.3.1 MICROEMULSION-BASED FORMULATIONS LEAD TO
BETTER OCULAR DRUG ADSORPTION 110
TABLE 35 OPHTHALMIC DRUG DELIVERY MARKET, BY COUNTRY,
2020–2027 (USD BILLION) 112
7.4 VAGINAL DRUG DELIVERY 112
7.4.1 RICH AND COMPLEX NETWORK OF CAPILLARIES OF
UPPER VAGINA TO CREATE SYSTEMIC DRUG DELIVERY SYSTEM 112
TABLE 36 VAGINAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 113
7.5 RECTAL DRUG DELIVERY 114
7.5.1 RECTAL ADMINISTRATION TO ENABLE BOTH LOCAL AND
SYSTEMIC THERAPY OF DRUGS 114
TABLE 37 RECTAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 115
7.6 NASAL DRUG DELIVERY 116
7.6.1 NASAL DELIVERY ROUTE OFFERS QUICK ONSET OF DRUG
ACTION AND CONVENIENCE AS COMPARED TO PARENTERAL ROUTE 116
TABLE 38 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 117
8 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE 118
8.1 INTRODUCTION 119
TABLE 39 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 119
8.2 HOMECARE SETTINGS 119
8.2.1 HOMECARE TO DOMINATE MARKET DURING FORECAST PERIOD 119
TABLE 40 TOPICAL DRUG DELIVERY MARKET FOR HOMECARE SETTINGS,
BY COUNTRY, 2020–2027 (USD BILLION) 121
8.3 HOSPITALS & CLINICS 121
8.3.1 TOPICAL ANAESTHETICS TO BE ADOPTED FOR VARIOUS MEDICAL AND SURGICAL SUB-SPECIALTIES 121
TABLE 41 TOPICAL DRUG DELIVERY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2027 (USD BILLION) 122
8.4 BURN CENTERS 123
8.4.1 TOPICAL ANTIMICROBIAL FORMULATIONS FOR BURN-RELATED INJURIES TO DRIVE MARKET GROWTH 123
TABLE 42 TOPICAL DRUG DELIVERY MARKET FOR BURN CENTERS, BY COUNTRY,
2020–2027 (USD BILLION) 124
8.5 OTHER FACILITIES 124
TABLE 43 TOPICAL DRUG DELIVERY MARKET FOR OTHER FACILITIES, BY COUNTRY, 2020–2027 (USD BILLION) 125
9 TOPICAL DRUG DELIVERY MARKET, BY REGION 126
9.1 INTRODUCTION 127
FIGURE 27 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 127
TABLE 44 TOPICAL DRUG DELIVERY MARKET, BY REGION, 2020–2027 (USD BILLION) 128
9.2 NORTH AMERICA 128
FIGURE 28 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET SNAPSHOT 129
TABLE 45 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY,
2020–2027 (USD BILLION) 130
TABLE 46 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 130
TABLE 47 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 130
TABLE 48 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 131
TABLE 49 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 131
TABLE 50 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 131
TABLE 51 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 132
TABLE 52 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION) 132
9.2.1 US 133
9.2.1.1 Rising prevalence of skin diseases alongside approval and launch of innovative topical formulations to propel market growth 133
TABLE 53 US: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION) 134
TABLE 54 US: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 134
TABLE 55 US: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 134
TABLE 56 US: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 135
TABLE 57 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2020–2027 (USD BILLION) 135
TABLE 58 US: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 135
TABLE 59 US: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION) 136
9.2.2 CANADA 136
9.2.2.1 Rising prevalence of hypertension and funding for topical drugs research to drive market growth 136
TABLE 60 CANADA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION) 137
TABLE 61 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 137
TABLE 62 CANADA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 137
TABLE 63 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 138
TABLE 64 CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 138
TABLE 65 CANADA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 138
TABLE 66 CANADA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 139
9.3 EUROPE 139
TABLE 67 RECENT DEVELOPMENTS IN EUROPEAN TOPICAL DRUG DELIVERY MARKET, 2019–2022 140
TABLE 68 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY,
2020–2027 (USD BILLION) 141
TABLE 69 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 141
TABLE 70 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 142
TABLE 71 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 142
TABLE 72 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 142
TABLE 73 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 143
TABLE 74 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 143
TABLE 75 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 143
9.3.1 GERMANY 144
9.3.1.1 Growing focus of pharmaceutical companies on topical products development and increasing target diseases to drive market growth 144
TABLE 76 DEVELOPMENTS AND PRODUCT LAUNCHES IN TOPICAL DRUG DELIVERY IN GERMANY, 2019–2022 144
TABLE 77 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 145
TABLE 78 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 145
TABLE 79 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 145
TABLE 80 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 146
TABLE 81 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 146
TABLE 82 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 146
TABLE 83 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 147
9.3.2 UK 147
9.3.2.1 Increasing developments by top players and demand for pain-free treatment to drive market growth 147
TABLE 84 UK: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 148
TABLE 85 UK: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 148
TABLE 86 UK: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 149
TABLE 87 UK: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 149
TABLE 88 UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2020–2027 (USD MILLION) 149
TABLE 89 UK: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 150
TABLE 90 UK: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 150
9.3.3 FRANCE 150
9.3.3.1 Rising prevalence of diabetes and increasing geriatric population to support market growth 150
TABLE 91 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 151
TABLE 92 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 151
TABLE 93 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 152
TABLE 94 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 152
TABLE 95 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 152
TABLE 96 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 153
TABLE 97 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 153
9.3.4 ITALY 153
9.3.4.1 Rising number of smokers to propel transdermal patches demand 153
TABLE 98 ITALY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 154
TABLE 99 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 154
TABLE 100 ITALY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 155
TABLE 101 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 155
TABLE 102 ITALY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2020–2027 (USD BILLION) 155
TABLE 103 ITALY: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 156
TABLE 104 ITALY: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 156
9.3.5 SPAIN 156
9.3.5.1 Growing diabetic patients to drive market growth 156
TABLE 105 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 157
TABLE 106 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 158
TABLE 107 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 158
TABLE 108 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 158
TABLE 109 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 159
TABLE 110 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 159
TABLE 111 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 160
9.3.6 SWITZERLAND 160
9.3.6.1 Rising geriatric population and emerging players focusing on topical drugs development to drive market growth 160
TABLE 112 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 161
TABLE 113 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 161
TABLE 114 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 162
TABLE 115 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 162
TABLE 116 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 162
TABLE 117 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 163
TABLE 118 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION) 163
9.3.7 REST OF EUROPE 163
TABLE 119 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 164
TABLE 120 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 165
TABLE 121 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 165
TABLE 122 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 165
TABLE 123 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 166
TABLE 124 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 166
TABLE 125 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION) 167
9.4 ASIA PACIFIC 167
FIGURE 29 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET SNAPSHOT 168
TABLE 126 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY,
2020–2027 (USD BILLION) 169
TABLE 127 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 169
TABLE 128 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION) 170
TABLE 129 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 170
TABLE 130 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 170
TABLE 131 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 171
TABLE 132 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 171
TABLE 133 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION) 172
9.4.1 CHINA 172
9.4.1.1 Prevalence of diabetes and increase in pharmaceutical R&D investments to drive market growth 172
TABLE 134 CHINA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 173
TABLE 135 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION) 173
TABLE 136 CHINA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 173
TABLE 137 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 174
TABLE 138 CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 174
TABLE 139 CHINA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 174
TABLE 140 CHINA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 175
9.4.2 JAPAN 175
9.4.2.1 Increasing number of product approvals and growing focus of local players on topical formulations R&D to support market growth 175
TABLE 141 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 176
TABLE 142 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION) 176
TABLE 143 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 176
TABLE 144 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 177
TABLE 145 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 177
TABLE 146 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 177
TABLE 147 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 178
9.4.3 INDIA 178
9.4.3.1 Rising awareness among healthcare providers and patients alongside increasing focus on noninvasive methods of drug delivery to drive market growth 178
TABLE 148 INDIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 179
TABLE 149 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION) 179
TABLE 150 INDIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 180
TABLE 151 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 180
TABLE 152 INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2020–2027 (USD MILLION) 180
TABLE 153 INDIA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 181
TABLE 154 INDIA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 181
9.4.4 AUSTRALIA 181
9.4.4.1 Increasing number of smokers to drive market growth 181
TABLE 155 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 182
TABLE 156 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 182
TABLE 157 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 183
TABLE 158 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 183
TABLE 159 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 183
TABLE 160 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 184
TABLE 161 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 184
9.4.5 REST OF ASIA PACIFIC 184
TABLE 162 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION) 185
TABLE 163 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 186
TABLE 164 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 186
TABLE 165 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 186
TABLE 166 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 187
TABLE 167 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 187
TABLE 168 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET,
BY FACILITY OF USE, 2020–2027 (USD BILLION) 187
9.5 LATIN AMERICA 188
TABLE 169 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY,
2020–2027 (USD BILLION) 188
TABLE 170 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 189
TABLE 171 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION) 189
TABLE 172 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 189
TABLE 173 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 190
TABLE 174 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 190
TABLE 175 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 190
TABLE 176 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION) 191
9.5.1 BRAZIL 191
9.5.1.1 High prevalence of diabetes to propel market growth 191
TABLE 177 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 192
TABLE 178 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION) 192
TABLE 179 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 192
TABLE 180 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 193
TABLE 181 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 193
TABLE 182 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 193
TABLE 183 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 194
9.5.2 MEXICO 194
9.5.2.1 Increasing prevalence of glaucoma to drive market growth 194
TABLE 184 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 195
TABLE 185 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION) 195
TABLE 186 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 195
TABLE 187 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 196
TABLE 188 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 196
TABLE 189 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 196
TABLE 190 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 197
9.5.3 REST OF LATIN AMERICA 197
TABLE 191 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION) 198
TABLE 192 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 198
TABLE 193 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 199
TABLE 194 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 199
TABLE 195 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 199
TABLE 196 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET,
BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 200
TABLE 197 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET,
BY FACILITY OF USE, 2020–2027 (USD BILLION) 200
9.6 MIDDLE EAST & AFRICA 200
9.6.1 GROWING PREVALENCE OF BURN INJURIES AND INCREASING EXPENDITURE ON HEALTHCARE TO DRIVE MARKET GROWTH 200
TABLE 198 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION) 201
TABLE 199 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR
SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION) 201
TABLE 200 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 202
TABLE 201 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 202
TABLE 202 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 202
TABLE 203 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 203
TABLE 204 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION) 203
10 COMPETITIVE LANDSCAPE 204
10.1 OVERVIEW 204
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 204
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS 205
10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 206
FIGURE 30 REVENUE ANALYSIS OF TOP PLAYERS IN TOPICAL DRUG DELIVERY MARKET 207
10.4 MARKET SHARE ANALYSIS 207
FIGURE 31 TOPICAL DRUG DELIVERY MARKET SHARE, BY KEY PLAYER, 2021 208
TABLE 205 TOPICAL DRUG DELIVERY MARKET: DEGREE OF COMPETITION 208
10.5 COMPETITIVE LEADERSHIP MAPPING 210
10.5.1 STARS 210
10.5.2 EMERGING LEADERS 210
10.5.3 PERVASIVE PLAYERS 210
10.5.4 PARTICIPANTS 210
FIGURE 32 TOPICAL DRUG DELIVERY MARKET: COMPETITIVE
LEADERSHIP MAPPING (2021) 211
10.6 COMPETITIVE LEADERSHIP MAPPING FOR OTHER PLAYERS 211
10.6.1 PROGRESSIVE COMPANIES 211
10.6.2 DYNAMIC COMPANIES 212
10.6.3 STARTING BLOCKS 212
10.6.4 RESPONSIVE COMPANIES 212
FIGURE 33 TOPICAL DRUG DELIVERY MARKET: COMPETITIVE LEADERSHIP
MAPPING FOR OTHER PLAYERS (2021) 212
10.7 COMPANY FOOTPRINT 213
TABLE 206 COMPANY FOOTPRINT: TOPICAL DRUG DELIVERY MARKET 213
10.7.1 PRODUCT FOOTPRINT OF MAJOR PLAYERS 214
TABLE 207 PRODUCT FOOTPRINT: TOPICAL DRUG DELIVERY MARKET (2021) 214
10.7.2 ROUTE OF ADMINISTRATION FOOTPRINT OF TOPICAL
DRUG DELIVERY MARKET 215
TABLE 208 ROUTE OF ADMINISTRATION FOOTPRINT:
TOPICAL DRUG DELIVERY MARKET (2021) 215
10.7.3 FACILITY OF USE IN TOPICAL DRUG DELIVERY MARKET 216
TABLE 209 FACILITY OF USE FOOTPRINT: TOPICAL DRUG DELIVERY MARKET (2021) 216
10.7.4 GEOGRAPHIC FOOTPRINT OF MAJOR PLAYERS IN TOPICAL
DRUG DELIVERY MARKET 217
TABLE 210 GEOGRAPHIC FOOTPRINT: TOPICAL DRUG DELIVERY MARKET (2021) 217
10.8 COMPETITIVE SCENARIO 218
10.8.1 PRODUCT LAUNCHES 218
TABLE 211 PRODUCT LAUNCHES, JANUARY 2019–APRIL 2022 218
10.8.2 DEALS 219
TABLE 212 DEALS, JANUARY 2019–APRIL 2022 219
10.8.3 OTHER DEVELOPMENTS 221
TABLE 213 OTHER DEVELOPMENTS, JANUARY 2019–APRIL 2022 221

ページTOPに戻る

Table of Contents

Summary

The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods.

“The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.”
Based on products, the topical drug delivery the market is segmented into semi-solid formulations, liquid formulations, solid formulations, and transdermal products. The large share of semi-solid formulations segment is attributed to better patient adherence with limited side effects, more absorption, provide efficiency in drug release, and does not harm the gastrointestinal tract.

“Dermal drug delivery accounted for the largest share of the market.”
Based on the route of administration, the market is segmented into dermal, ophthalmic, rectal, vaginal, and nasal drug delivery. The large share of the dermal drug delivery market segment can largely be attributed to accessible product launches and adoption as they have fewer regulatory requirements, enhancement of penetrations and permeation of drugs as they are delivered through skin, and less irritation in patients as compared to nasal or ophthalmic drug delivery.

“Home care settings hold the largest share in the market, by facility of use”
Based on the facility of use, the market is segmented into home care settings, hospitals & clinics, burn centers, and other facilities. The large share of home care settings segment can be attributed to better patient comfort, growing awareness regarding home care settings is improving patient acceptability, decline in hospital visits due to COVID-19 pandemic, and shift in trend from treatments carried out in hospitals and nursing homes to treatments at home due to cost-effectiveness of home care settings.

“The APAC to witness the highest growth during the forecast period.”
Asia Pacific is expected to grow at the highest CAGR during the forecast period of 2022–2027. The high incidence of skin diseases (such as skin cancer), the rising prevalence of chronic diseases (such as diabetes), increasing use of contraceptives, the increasing geriatric population, and the growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems are some of the major factors that are expected to drive the growth of the topical drug delivery market in the Asia Pacific region.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–35%, Tier 2–45%, and Tier 3–20%
• By Designation – C-level–35%, Director-level–25%, Others–40%
• By Region – North America–45%, Europe–30%, Asia Pacific–20%, Latin America- 3%, Middle East and Africa–2%

Key players in the Topical Drug Delivery Market

The prominent players in the topical drug delivery market are Glenmark Pharmaceuticals Ltd. (India), Galderma (Switzerland), Johnson & Johnson Private Limited (US), GlaxoSmithKline Plc. (UK), Bausch Health Companies Inc. (Canada), Hisamitsu Pharmaceuticals Inc. (Japan), Cipla (India), Bayer AG (Germany), Viatris Inc. (Mylan N.V.) (US), 3M (US), Merck & Co.Inc.. (Germany), Crescita Therpeautics Inc. (Canada), Novartis International AG (Switzerland), Boehringer Ingelheim International GmBH (Germany), Pfizer Inc. (US), Teva Pharmaceuticals Industries Ltd. (Israel), Bristol Myers Squibb (US), Lead Chemical Co., Ltd. (Japan), Purdue Pharma L.P. (US), Lavipharm (Greece), AbbVie Inc. (US), CMP Pharma, Inc. (Germany), Encore Dermatology, Inc. (US), Prosolus Inc. (US), and Rusan Pharma Ltd. (India).

Research Coverage:
The report analyzes the topical drug delivery market and aims at estimating the market size and future growth potential of this market based on various segments such as product, route of administration, facility of use, and region. The report also includes a product portfolio matrix of various topical drug delivery products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the topical drug delivery market. The report analyzes this market by product, by route of administration, and by facility of use.
• Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global topical drug delivery market
• Market Development: Comprehensive information on the lucrative emerging markets by product, route of administration, and facility of use
• Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global topical drug delivery market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global topical drug delivery market.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（その他）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（homecare）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（その他）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（homecare）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?